Healthy
Conditions
Brief summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3540378 in healthy participants following single and multiple doses (Parts A and B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood tests will be performed to check how much LY3540378 gets into the bloodstream and how long it takes the body to eliminate it. This is a 4-part study and may last up to 70, 113, 113 and 113 days for each participant in Parts A, B, C, and D respectively.
Interventions
DRUGLY3540378
Administered IV or SC.
DRUGPlacebo
Administered IV or SC.
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Overtly healthy males or females, as determined by medical history and physical examination. * Body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²) * For Part C, participants should be first generation Japanese origin. * For Part D, participants should be first generation Chinese origin. * Male participants must agree to adhere to contraception restrictions and female participants not of childbearing potential and may include who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), or congenital anomaly such as müllerian agenesis or postmenopausal
Exclusion criteria
* Participants with troponin I results above the upper reference limit judged to be clinically significant by the investigator * Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within 3 minutes of standing when compared with blood pressure from the sitting or supine position. * Have a significant history of or current cardiovascular (for example, myocardial infarction, congestive HF, cerebrovascular accident, venous thromboembolism, etc.), respiratory, renal, gastrointestinal, endocrine, haematological (including history of thrombocytopenia), or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs * Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis biliary and pancreatic disorder * Have evidence of significant active neuropsychiatric disease as determined by the investigator * Have received chronic (lasting \>14 consecutive days) systemic glucocorticoid therapy in the past year, or have received any glucocorticoid therapy within 1 month before screening * Have an abnormality in the 12-lead ECG * Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2 × the upper limit of normal (ULN) or total bilirubin (TBL) \>1.5 × ULN * Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase greater than 1.5 × ULN * Have known allergies to LY3540378 or related compounds * Have donated blood of \>450 mL, or have participated in a clinical study that required similar blood volume drawn within the past 30 calendar days * Have an average weekly alcohol intake that exceeds 7 units per week, or are unwilling to stop alcohol consumption as required during the study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) * Smoke \>10 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine * Allergy to iodine (shellfish allergy) * Have a history of sensitivity to lithium carbonate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Baseline up to Day 113 | A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3540378 | Predose on Day 1 through Day 113 | PK: Cmax of LY3540378 |
| PK: Area Under the Concentration Versus Time Curve (AUC) of LY3540378 | Predose on Day 1 through Day 113 | PK: AUC of LY3540378 |
Countries
Singapore, United States
Outcome results
None listed